{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:13Z","timestamp":1787020993698,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82203821"],"award-info":[{"award-number":["No. 82203821"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00859-6","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:54:03Z","timestamp":1741942443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study"],"prefix":"10.1186","volume":"26","author":[{"given":"Huan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunrui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fantong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangdong","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"1","key":"859_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"859_CR2","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563\u201379.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10026","key":"859_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415\u201326.","journal-title":"Lancet"},{"key":"859_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.lungcan.2017.02.003","volume":"106","author":"G Metro","year":"2017","unstructured":"Metro G, Tazza M, Matocci R, Chiari R, Crin\u00f2 L. Optimal management of ALK -positive NSCLC progressing on crizotinib. Lung Cancer. 2017;106:58\u201366.","journal-title":"Lung Cancer"},{"issue":"12","key":"859_CR5","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","volume":"30","author":"D Moro-Sibilot","year":"2019","unstructured":"Moro-Sibilot D, Cozic N, P\u00e9rol M, Mazi\u00e8res J, Otto J, Souquet PJ, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial. Ann Oncol. 2019;30(12):1985\u201391.","journal-title":"Ann Oncol"},{"issue":"21","key":"859_CR6","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou SHI, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1 -Rearranged non\u2013small-cell lung cancer. N Engl J Med. 2014;371(21):1963\u201371.","journal-title":"N Engl J Med"},{"key":"859_CR7","doi-asserted-by":"publisher","first-page":"iii35","DOI":"10.1093\/annonc\/mdw304","volume":"27","author":"F Blackhall","year":"2016","unstructured":"Blackhall F, Cappuzzo F. Crizotinib: from discovery to accelerated development to front-line treatment. Ann Oncol. 2016;27:iii35\u201341.","journal-title":"Ann Oncol"},{"issue":"10","key":"859_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","volume":"13","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011\u20139.","journal-title":"Lancet Oncol"},{"key":"859_CR9","doi-asserted-by":"publisher","first-page":"e000219","DOI":"10.1136\/esmoopen-2017-000219","volume":"2","author":"F Blackhall","year":"2017","unstructured":"Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced\/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017;2:e000219.","journal-title":"ESMO Open"},{"issue":"25","key":"859_CR10","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crin\u00f3 L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK -positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med"},{"issue":"22","key":"859_CR11","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","volume":"36","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non\u2013small-cell lung cancer. J Clin Oncol. 2018;36(22):2251\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"859_CR12","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin Y, Shu Y, Zhu J, Li F, Li J. A real-world pharmacovigilance study of FDA adverse event reporting System (FAERS) events for osimertinib. Sci Rep. 2022;12(1):19555.","journal-title":"Sci Rep"},{"issue":"8","key":"859_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiology Drug. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiology Drug"},{"issue":"6","key":"859_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiology Drug"},{"issue":"4","key":"859_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"30","key":"859_CR16","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","volume":"39","author":"S Heo","year":"2020","unstructured":"Heo S, Jung I. Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance. Stat Med. 2020;39(30):4636\u201350.","journal-title":"Stat Med"},{"issue":"6","key":"859_CR17","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","volume":"6","author":"NE Omar","year":"2021","unstructured":"Omar NE, Fahmy Soliman AI, Eshra M, Saeed T, Hamad A, Abou-Ali A. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA adverse event reporting System (FAERS). ESMO Open. 2021;6(6):100315.","journal-title":"ESMO Open"},{"key":"859_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lungcan.2022.09.010","volume":"173","author":"C De La Aguado","year":"2022","unstructured":"Aguado De La Rosa C, Cruz Castellanos P, L\u00e1zaro-Quintela M, D\u00f3mine M, V\u00e1zquez Est\u00e9vez S, L\u00f3pez-Vivanco G, et al. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). Lung Cancer. 2022;173:83\u201393.","journal-title":"Lung Cancer"},{"issue":"1","key":"859_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78\u201384.","journal-title":"Lung Cancer"},{"issue":"18","key":"859_CR20","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer. N Engl J Med. 2010;363(18):1693\u2013703.","journal-title":"N Engl J Med"},{"issue":"1","key":"859_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/toxsci\/kfu213","volume":"143","author":"CN Liu","year":"2015","unstructured":"Liu CN, Mathialagan N, Lappin P, Fortner J, Somps C, Seitis G, et al. Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition. Toxicol Sci. 2015;143(1):116\u201325.","journal-title":"Toxicol Sci"},{"key":"859_CR22","doi-asserted-by":"publisher","first-page":"858279","DOI":"10.3389\/fphar.2022.858279","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Chen C, Rong C, He X, Chen L. Anaplastic lymphoma kinase tyrosine kinase inhibitor-associated cardiotoxicity: a recent five-year pharmacovigilance study. Front Pharmacol. 2022;13:858279.","journal-title":"Front Pharmacol"},{"issue":"4","key":"859_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","volume":"14","author":"A Gemma","year":"2019","unstructured":"Gemma A, Kusumoto M, Kurihara Y, Masuda N, Banno S, Endo Y, et al. Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib. J Thorac Oncol. 2019;14(4):672\u201382.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"859_CR24","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1097\/JTO.0000000000000577","volume":"10","author":"P Cr\u00e9quit","year":"2015","unstructured":"Cr\u00e9quit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, et al. Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review. J Thorac Oncol. 2015;10(8):1148\u201355.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"859_CR25","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1200\/JCO.2012.43.3730","volume":"31","author":"A Tamiya","year":"2013","unstructured":"Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK\u2013Positive non\u2013small-cell Lung cancer. JCO. 2013;31(1):e15\u20137.","journal-title":"JCO"},{"key":"859_CR26","doi-asserted-by":"publisher","first-page":"115636","DOI":"10.1016\/j.bcp.2023.115636","volume":"215","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Gao Z, Pan Z, Fu H, Jiang F, Yan H, et al. Crizotinib induces pulmonary toxicity by blocking autophagy flux in alveolar epithelial cells. Biochem Pharmacol. 2023;215:115636.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"859_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40248-015-0021-4","volume":"10","author":"C Vitale","year":"2015","unstructured":"Vitale C, D\u2019Amato M, Calabr\u00f2 P, Stanziola AA, Mormile M, Molino A. Venous thromboembolism and lung cancer: a review. Multidiscip Respir Med. 2015;10(1):28.","journal-title":"Multidiscip Respir Med"},{"issue":"3","key":"859_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1378\/chest.13-2379","volume":"146","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Yang Y, Chen W, Guo L, Liang L, Zhai Z, et al. Prevalence and associations of VTE in patients with newly diagnosed Lung Cancer. Chest. 2014;146(3):650\u20138.","journal-title":"Chest"},{"issue":"1","key":"859_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cllc.2019.06.012","volume":"21","author":"R Chiari","year":"2020","unstructured":"Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, et al. ROS1-rearranged non\u2013small-cell lung Cancer is Associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, Multicenter, two-arms trial (METROS). Clin Lung Cancer. 2020;21(1):15\u201320.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"859_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11523-023-00973-7","volume":"18","author":"M Wang","year":"2023","unstructured":"Wang M, Slatter S, Sussell J, Lin CW, Ogale S, Datta D, et al. ALK inhibitor treatment patterns and outcomes in real-world patients with ALK-Positive non-small-cell lung cancer: a retrospective cohort study. Targ Oncol. 2023;18(4):571\u201383.","journal-title":"Targ Oncol"},{"issue":"4","key":"859_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547\u201362.","journal-title":"Cancer Cell"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00859-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:54:08Z","timestamp":1741942448000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00859-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00859-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}